Tenax presents LEVEL topline results; primary endpoint neutral
Tenax reported topline and comprehensive LEVEL results, including about a 49% NT-proBNP reduction and a 3.5 mmHg decline in RVSP, while the trial missed its primary 6MWD endpoint.
Tenax reported LEVEL topline and comprehensive results showing ~49% NT-proBNP reduction and a 3.5 mmHg decline in RVSP, while the trial missed its primary 6MWD endpoint.Key Highlights:Original SEC Filing: TENAX THERAPEUTICS, INC. [ TENX ] - 8-K - Sep. 09, 2026This is an AI-powered summary. It may c…